Current and emerging biomarkers in breast cancer: prognosis and prediction

1. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 1

   Time to recurrence for (A and C) tamoxifen-treated and (B and D) anastrozole-treated patients included in the ATAC trial, grouped according to the quartile (Q) of (A and B) estrogen receptor H-score and (C and D) progesterone receptor percentage staining quartiles. Reprinted with permission. 2008 American Society of Clinical Oncology. All rights reserved. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al. 2008 Journal of Clinical Oncology 26 1059–1065.
2. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 2

   Recurrence-free survival according to tertiles of tumor Ki67 expression at baseline (top panel) and after 2 weeks of treatment (bottom panel) from patients included in the IMPACT trial. Reprinted with permission from Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99 167–170. Oxford University Press, 2007.
3. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 3

   Predicted risk of recurrence by recurrence score (RS) and Adjuvant! Online for patients with ER-positive node-negative disease treated with tamoxifen or anastrozole adjuvant therapy in the absence of chemotherapy (n=872). Reprinted with permission. 2008 American Society of Clinical Oncology. All rights reserved. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A et al. 2010 Journal of Clinical Oncology 28 1829–1834.

• © 2010 Society for Endocrinology